Skip to main content

Proxeon Raises $2.4M from VC Investors

NEW YORK (GenomeWeb News) – Danish proteomics firm Proxeon has raised DKK14 million ($2.4 million) in a round of private financing from venture capital investors.

The firm did not say in its statement who the venture capital investors are for this round, but according to the firm's website investment firms Vecata and Inventure Capital are among its investors.

Proxeon said that the investment is expected to be sufficient to help the firm reach positive cash flow. It also noted that it expects to record full-year 2008 revenue growth of more than 60 percent.

Proxeon CEO Martin Winge noted that the firm has shipped more than 100 of its Easy-nLC systems for nanoscale chromatography since its launch in 2006.

The Scan

And For Adolescents

The US Food and Drug Administration has authorized the Pfizer-BioNTech SARS-CoV-2 vaccine for children between the ages of 12 and 15 years old.

Also of Concern to WHO

The Wall Street Journal reports that the World Health Organization has classified the SARS-CoV-2 variant B.1.617 as a "variant of concern."

Test for Them All

The New York Times reports on the development of combined tests for SARS-CoV-2 and other viruses like influenza.

PNAS Papers on Oral Microbiome Evolution, Snake Toxins, Transcription Factor Binding

In PNAS this week: evolution of oral microbiomes among hominids, comparative genomic analysis of snake toxins, and more.